0.8556
price down icon0.36%   -0.0031
after-market アフターアワーズ: .84 -0.0156 -1.82%
loading
前日終値:
$0.8587
開ける:
$0.8655
24時間の取引高:
77,415
Relative Volume:
0.12
時価総額:
$10.14M
収益:
-
当期純損益:
$-7.51M
株価収益率:
-0.6482
EPS:
-1.32
ネットキャッシュフロー:
$-8.02M
1週間 パフォーマンス:
+8.63%
1か月 パフォーマンス:
-17.73%
6か月 パフォーマンス:
+1.86%
1年 パフォーマンス:
-26.87%
1日の値動き範囲:
Value
$0.8259
$0.8655
1週間の範囲:
Value
$0.74
$0.869
52週間の値動き範囲:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
名前
Hoth Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
(646)756-2997
Name
住所
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
職員
3
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
HOTH's Discussions on Twitter

HOTH を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
HOTH
Hoth Therapeutics Inc
0.8556 10.14M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2019-10-15 開始されました The Benchmark Company Speculative Buy

Hoth Therapeutics Inc (HOTH) 最新ニュース

pulisher
Apr 21, 2025

Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

Revolutionary RNA Cancer Treatment Gets Japanese Patent: Hoth's KIT Gene Therapy Targets Multiple Cancers - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics reports progress in pruritus treatment trial - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial - Longview News-Journal

Apr 15, 2025
pulisher
Apr 03, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com Nigeria

Apr 03, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics (HOTH) Reports Promising Data for Alzheimer's Candidate HT-ALZ - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Flat on Hookup with Washington Univ. - Baystreet.ca

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ - Longview News-Journal

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours - PR Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage - PR Newswire

Mar 31, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 20, 2025

Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Hoth reports progress in GIST treatment with HT-KIT - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan

Mar 18, 2025
pulisher
Mar 17, 2025

Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World

Mar 17, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Dips on Drug Application - Baystreet.ca

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks

Mar 05, 2025

Hoth Therapeutics Inc (HOTH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
大文字化:     |  ボリューム (24 時間):